Clear market notes built around the JSE, the rand, and what matters locally.

2026-09-30 21:30 • The Motley Fool Positive Axe Cap view: Selective

Cantor Fitzgerald maintains a neutral rating on Rivian while setting a $19 price target, implying 20% upside. The article argues Rivian's valuation is underappreciated relative to Tesla, citing growth potential from its affordable R2 SUV launch and exposure to the robotaxi market. Rivian's gross margins of 2% lag Tesla's 19%, but could improve with economies of scale. The company is positioning itself as a supplier to robotaxi operators like Uber, which agreed to purchase up to 50,000 R2 SUVs.

Axe note: Rivian targets growth with affordable SUVs and robotaxi deals, but South African investors should approach with caution.

2026-09-30 21:21 • The Motley Fool Positive Axe Cap view: Selective

Celcuity stock gained 2.8% on Wednesday as the biotech company launched its first FDA-approved drug, Revtorpyk, for HR+/HER2 breast cancer treatment. The company also introduced support services for patients and physicians. The stock outperformed the broader market, which saw the S&P 500 decline 0.3%.

Axe note: Celcuity’s stock rose after FDA approval of its breast cancer drug, signaling early optimism.

2026-09-30 21:20 • The Motley Fool Mixed Axe Cap view: Selective

Nvidia announced an additional $150 billion share repurchase authorization, bringing its total buyback program to $235 billion through 2028. The company closed up 0.52% at $228.38, supported by positive developments including an AI safety accord and expansion into quantum computing. With 106% year-over-year revenue growth and a forward P/E ratio of 25, Nvidia continues to solidify its position as a leading AI company.

Axe note: Nvidia’s $150 billion share buyback shows strength in AI, yet South African investors should watch USD/ZAR for local impact.